反応式
[CH3:1][C@H:2]1[CH2:7][CH2:6][N:5]([C:8]([O:10][C:11]([CH3:14])([CH3:13])[CH3:12])=[O:9])[CH2:4][C@H:3]1[C:15](=S)[NH:16][CH2:17][C:18]1[N:19]=[C:20]2[CH:26]=[CH:25][N:24]([S:27]([C:30]3[CH:36]=[CH:35][C:33]([CH3:34])=[CH:32][CH:31]=3)(=[O:29])=[O:28])[C:21]2=[N:22][CH:23]=1>O1CCOCC1.FC(F)(F)C([O-])=O.[Hg+2].FC(F)(F)C([O-])=O>[C:11]([O:10][C:8]([N:5]1[CH2:6][CH2:7][C@H:2]([CH3:1])[C@H:3]([C:15]2[N:19]3[C:20]4[CH:26]=[CH:25][N:24]([S:27]([C:30]5[CH:36]=[CH:35][C:33]([CH3:34])=[CH:32][CH:31]=5)(=[O:28])=[O:29])[C:21]=4[N:22]=[CH:23][C:18]3=[CH:17][N:16]=2)[CH2:4]1)=[O:9])([CH3:14])([CH3:13])[CH3:12]参加物
反応物 1
生成物 1
試薬・触媒・溶媒 2
実験手順
A round bottom flask was charged with cis-tert-butyl 4-methyl-3-((5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)methylcarbamoyl)piperidine-1-carboxylate (5.62 g, 10.6 mmol, prepared using O from 4-methylnicotonic acid, M, H from Example #5, Step C, HATU and DIEA) and Lawesson's reagent (3.0 g, 7.4 mmol) in 1,4-dioxane (100 mL). The reaction was heated at about 80° C. for about 1 h, cooled to ambient temperature, and concd under reduced pressure. The crude product was dissolved in EtOAc (200 mL) and washed with saturated aqueous NaHCO3 (3×100 mL). The organic layer was separated, dried over anhydrous MgSO4, filtered, and concd under reduced pressure. The material was purified by silica gel chromatography eluting with a gradient of 0-5% MeOH in DCM to afford cis-tert-butyl 4-methyl-3-((5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)methylcarbamothioyl)piperidine-1-carboxylate (5.2 g, 90%): LC/MS (Table 1, Method b) Rt=2.65 min; MS m/z: 544 (M+H)+. A round bottom flask was charged with cis-tert-butyl 4-methyl-3-((5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)methylcarbamothioyl)piperidine-1-carboxylate (2.6 g, 4.8 mmol) and mercury (II) trifluoroacetate (2.1 g, 4.8 mmol) in 1,4-dioxane (72 mL) and stirred at ambient temperature for about 1 h. The reaction mixture was filtered through a pad of Celite®. The Celite® pad was rinsed with DCM (30 mL) and EtOAc (30 mL). The filtrate was concd under reduced pressure. The residue was dissolved in DCM (50 mL) and washed with saturated aqueous sodium thiosulfate (10 mL), and saturated aqueous NaHCO3 (25 mL), dried over anhydrous MgSO4, filtered, and concd under reduced pressure. The material was purified by silica gel chromatography eluting with a gradient of 0-5% MeOH in DCM to afford cis-tert-butyl-4-methyl-3-(6-tosyl-6H-imidazo[1,5-a]pyrrolo[2,3-e]pyrazin-1-yl)piperidine-1-carboxylate (2.2 g, 90%): LC/MS (Table 1, Method b) Rt=2.57 min; MS m/z: 510 (M+H)+.
後処理
- filtrationThe reaction mixture was filtered through a pad of Celite®
- washThe Celite® pad was rinsed with DCM (30 mL) and EtOAc (30 mL)
- dissolutionThe residue was dissolved in DCM (50 mL)
- washwashed with saturated aqueous sodium thiosulfate (10 mL), and saturated aqueous NaHCO3 (25 mL)
- dry with materialdried over anhydrous MgSO4
- filtrationfiltered
- customThe material was purified by silica gel chromatography
- washeluting with a gradient of 0-5% MeOH in DCM
出典と根拠
- ORDレコード
- ord-e71e49bf9e41442fbe78e547f58931d7
- 出典データセット
- uspto-grants-2013_04
- 特許番号
- US08426411B2
関連ノート
読み込み中…